|
EP3349802B1
(en)
*
|
2015-09-14 |
2021-08-04 |
The Board of Regents of the University of Texas System |
Lipocationic dendrimers and uses thereof
|
|
IL314915B1
(en)
|
2017-01-23 |
2026-02-01 |
Regeneron Pharma |
Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
|
|
KR20190139869A
(ko)
|
2017-04-11 |
2019-12-18 |
리제너론 파마슈티칼스 인코포레이티드 |
하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
|
|
WO2019028032A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
|
|
CN111182790A
(zh)
|
2017-07-31 |
2020-05-19 |
瑞泽恩制药公司 |
Crispr报告体非人类动物及其用途
|
|
MX394999B
(es)
|
2017-09-29 |
2025-03-24 |
Regeneron Pharma |
Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
|
|
US10961583B2
(en)
|
2017-10-11 |
2021-03-30 |
Regeneron Phramaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
CN111885915B
(zh)
|
2018-03-19 |
2023-04-28 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
JP7507093B2
(ja)
|
2018-03-21 |
2024-06-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
１７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
|
|
US12357580B2
(en)
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
WO2020051220A1
(en)
*
|
2018-09-04 |
2020-03-12 |
The Board of the Regents of the University of Texas System |
Compositions and methods for organ specific delivery of nucleic acids
|
|
CN112996519B
(zh)
*
|
2018-09-04 |
2025-02-28 |
德克萨斯大学系统董事会 |
用于核酸的器官特异性递送的组合物和方法
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
US11622547B2
(en)
|
2019-06-07 |
2023-04-11 |
Regeneran Pharmaceuticals, Inc. |
Genetically modified mouse that expresses human albumin
|
|
US11845957B2
(en)
|
2019-06-14 |
2023-12-19 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
|
KR20220044816A
(ko)
*
|
2019-08-12 |
2022-04-11 |
인티그레이티드 나노테라퓨틱스 아이엔씨. |
하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
CN111467321A
(zh)
*
|
2020-03-26 |
2020-07-31 |
深圳市新合生物医疗科技有限公司 |
一种mRNA核酸类药物胞内递送系统、制备方法和应用
|
|
WO2021216577A1
(en)
*
|
2020-04-20 |
2021-10-28 |
Board Of Regents, The University Of Texas System |
Lipid nanoparticle (lnp) delivery systems and uses thereof
|
|
GB202008821D0
(en)
*
|
2020-06-10 |
2020-07-22 |
Highersteaks Ltd |
Systems and methods for cell conversion
|
|
AU2021305214A1
(en)
*
|
2020-07-10 |
2023-02-23 |
Genevant Sciences Gmbh |
Lipid nanoparticles for delivering therapeutics to lungs
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
JP2024511463A
(ja)
|
2021-03-22 |
2024-03-13 |
リコード セラピューティクス，インク． |
細胞への標的送達のための組成物および方法
|
|
JP2024511437A
(ja)
|
2021-03-23 |
2024-03-13 |
リコード セラピューティクス，インク． |
ポリヌクレオチド組成物、関連製剤、およびその使用方法
|
|
AU2022252396A1
(en)
*
|
2021-04-02 |
2023-11-16 |
Tiba Biotech Llc |
Dendritic architectures as nonviral vectors in gene delivery
|
|
KR102771369B1
(ko)
*
|
2021-04-13 |
2025-02-21 |
웨스트진 바이오파마 컴퍼니 리미티드 |
핵산 전달을 위한 이온화 가능한 지질 및 조성물
|
|
CN113637708B
(zh)
*
|
2021-08-09 |
2023-07-25 |
中国科学院过程工程研究所 |
一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
CN118632622A
(zh)
|
2021-12-08 |
2024-09-10 |
瑞泽恩制药公司 |
突变型肌纤蛋白疾病模型及其用途
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
AU2022425201A1
(en)
*
|
2021-12-27 |
2024-07-18 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for targeted delivery to cells
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
CN119654166A
(zh)
|
2022-04-01 |
2025-03-18 |
内诺维什疗法股份有限公司 |
mRNA递送方法及其组合物
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
KR20250094676A
(ko)
*
|
2022-10-25 |
2025-06-25 |
나노베이션 테라퓨틱스 인크. |
안티-센스 올리고뉴클레오티드 전달을 위한 지질 나노입자 제형
|
|
WO2024112775A1
(en)
*
|
2022-11-25 |
2024-05-30 |
Beam Therapeutics Inc. |
Compositions and methods for editing a transthyretin gene
|
|
EP4630057A1
(en)
|
2022-12-08 |
2025-10-15 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2024138370A1
(zh)
*
|
2022-12-27 |
2024-07-04 |
北京炫景瑞医药科技有限公司 |
一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
|
|
AU2024231082A1
(en)
*
|
2023-03-09 |
2025-10-16 |
Maxirna (Shanghai) Pharmaceutical Co., Ltd. |
Ionizable lipid molecule, preparation method therefor and use thereof
|
|
EP4680595A2
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
CN116271105B
(zh)
*
|
2023-05-18 |
2023-08-25 |
上海贝斯昂科生物科技有限公司 |
一种适于rpe细胞转染的脂质纳米颗粒及其应用
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
US12599560B2
(en)
|
2023-11-02 |
2026-04-14 |
Longuide Biopharma Corporation |
Lipids and lipid nanoparticle formulations
|
|
WO2025091377A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Longuide Biopharma Corporation |
Lipids and lipid nanoparticle formulations
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|